Bluebirdbio downgraded by BofA Securities with a new price target

11/15/24 7:32:03 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

BofA Securities downgraded Bluebirdbio from Buy to Neutral and set a new price target of $0.50 from $3.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BLUE

Date	Price Target	Rating	Analyst
2/24/2025		Underweight → Neutral	Analyst
2/24/2025	$29.00	Overweight	Analyst
11/18/2024		Neutral → Underweight	Analyst
11/15/2024		Neutral → Underweight	JP Morgan
11/15/2024	$3.00 → $0.50	Buy → Neutral	BofA Securities
8/15/2024		Overweight → Neutral	JP Morgan
12/11/2023		Hold → Reduce	HSBC Securities
12/8/2023	$3.00 → $7.00	Underweight → Equal-Weight	Morgan Stanley